Ad
CYCCP Quote Trading Chart Cyclacel Pharmaceuticals Inc. 6%...
home / stock / cyccp / cyccp quote
$6.41 Last:
-1.38% Change Percent:
$6.88 Open:
$6.50 Previous Close:
$6.88 High:
$6.05 Low:
7,637 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
CYCCP Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2022-08-11 | 6.88 | 6.5 | 6.88 | 6.05 | 7,637 |
| 2022-08-10 | 6.5 | 6.5 | 6.5 | 6.5 | 156 |
| 2022-07-14 | 7 | 7.0001 | 7.0001 | 7 | 477 |
| 2022-07-13 | 7 | 7 | 7 | 7 | 271 |
| 2022-07-11 | 7.76 | 7.76 | 7.76 | 7.76 | 185 |
| 2022-07-08 | 7.72 | 7.75 | 7.75 | 7.72 | 422 |
| 2022-06-24 | 6.77 | 6.77 | 6.77 | 6.77 | 331 |
| 2022-06-20 | 6.71 | 6.71 | 6.71 | 6.71 | 106 |
| 2022-06-17 | 6.71 | 6.71 | 6.71 | 6.71 | 106 |
| 2022-06-16 | 6.13 | 6.13 | 6.13 | 6.12 | 601 |
| 2022-06-08 | 6.48 | 6.1 | 6.48 | 6.1 | 610 |
| 2022-06-03 | 7.12 | 7.12 | 7.12 | 7.12 | 301 |
| 2022-05-24 | 7 | 7.1 | 7.1 | 7 | 520 |
| 2022-05-10 | 6.48 | 6.48 | 6.48 | 6.48 | 100 |
| 2022-05-09 | 6.48 | 6.48 | 6.48 | 6.48 | 100 |
| 2022-05-06 | 6.48 | 6.48 | 6.48 | 6.48 | 103 |
| 2022-05-04 | 6.35 | 6.35 | 6.35 | 6.35 | 152 |
| 2022-05-02 | 6.2601 | 6.28 | 6.29 | 6.2601 | 502 |
| 2022-04-28 | 7.15 | 6.35 | 7.15 | 6.35 | 200 |
| 2022-04-26 | 6.92 | 6.92 | 6.92 | 6.92 | 100 |
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock Company Name:
CYCCP Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
Ad
-
- Oral fadraciclib demonstrated good tolerability with continuous dosing; anticipate entering Phase 2 POC stage in 2H 2022 – - Demonstrated evidence of target engagement for CDK2 and CDK9 – - Company to host R&D day in ...
-
BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results ...
-
- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors - - No Dose Limiting Toxicities Observed at All Dose Levels Enrolled to Date - - Demonstrated Evidence of Target Engagement for CDK2 and CDK9 - - Early Anticancer Activity...